<?xml version="1.0" encoding="us-ascii"?><inf:proxyVoteTable xmlns:inf="http://www.sec.gov/edgar/document/npxproxy/informationtable">
<!--VoteTableSchemaVersion:X0300-->
<inf:proxyTable><inf:issuerName>MEDTRONIC PLC</inf:issuerName><inf:cusip>G5960L103</inf:cusip><inf:isin>IE00BTN1Y115</inf:isin><inf:meetingDate>10/19/2023</inf:meetingDate><inf:voteDescription>Approving, on an advisory basis, the Company's executive compensation</inf:voteDescription><inf:voteCategories><inf:voteCategory><inf:categoryType>SECTION 14A SAY-ON-PAY VOTES</inf:categoryType></inf:voteCategory></inf:voteCategories><inf:voteSource>ISSUER</inf:voteSource><inf:sharesVoted>9637</inf:sharesVoted><inf:sharesOnLoan>0</inf:sharesOnLoan><inf:vote><inf:voteRecord><inf:howVoted>FOR</inf:howVoted><inf:sharesVoted>9637</inf:sharesVoted><inf:managementRecommendation>FOR</inf:managementRecommendation></inf:voteRecord></inf:vote></inf:proxyTable>
<inf:proxyTable><inf:issuerName>ZYMEWORKS INC.</inf:issuerName><inf:cusip>98985Y108</inf:cusip><inf:isin>US98985Y1082</inf:isin><inf:meetingDate>12/07/2023</inf:meetingDate><inf:voteDescription>Advisory vote on the compensation of named executive officers</inf:voteDescription><inf:voteCategories><inf:voteCategory><inf:categoryType>SECTION 14A SAY-ON-PAY VOTES</inf:categoryType></inf:voteCategory></inf:voteCategories><inf:voteSource>ISSUER</inf:voteSource><inf:sharesVoted>0</inf:sharesVoted><inf:sharesOnLoan>0</inf:sharesOnLoan><inf:vote><inf:voteRecord><inf:howVoted></inf:howVoted><inf:sharesVoted></inf:sharesVoted><inf:managementRecommendation></inf:managementRecommendation></inf:voteRecord></inf:vote></inf:proxyTable>
<inf:proxyTable><inf:issuerName>GALAPAGOS N V</inf:issuerName><inf:cusip>36315X101</inf:cusip><inf:isin>US36315X1019</inf:isin><inf:meetingDate>04/30/2024</inf:meetingDate><inf:voteDescription>Please refer to Appendix A of the Depositary Notice for the Shareholders' Meetings Agenda and Proposed Resolutions.</inf:voteDescription><inf:voteCategories><inf:voteCategory><inf:categoryType>SECTION 14A SAY-ON-PAY VOTES</inf:categoryType></inf:voteCategory></inf:voteCategories><inf:voteSource>ISSUER</inf:voteSource><inf:sharesVoted>181295</inf:sharesVoted><inf:sharesOnLoan>0</inf:sharesOnLoan><inf:vote><inf:voteRecord><inf:howVoted>FOR</inf:howVoted><inf:sharesVoted>181295</inf:sharesVoted><inf:managementRecommendation>FOR</inf:managementRecommendation></inf:voteRecord></inf:vote></inf:proxyTable>
<inf:proxyTable><inf:issuerName>PROTHENA CORPORATION PLC</inf:issuerName><inf:cusip>G72800108</inf:cusip><inf:isin>IE00B91XRN20</inf:isin><inf:meetingDate>05/14/2024</inf:meetingDate><inf:voteDescription>To approve, in a non-binding advisory vote, the compensation of the executive officers named in the Company's Proxy Statement for the Annual General Meeting</inf:voteDescription><inf:voteCategories><inf:voteCategory><inf:categoryType>SECTION 14A SAY-ON-PAY VOTES</inf:categoryType></inf:voteCategory></inf:voteCategories><inf:voteSource>ISSUER</inf:voteSource><inf:sharesVoted>14105</inf:sharesVoted><inf:sharesOnLoan>0</inf:sharesOnLoan><inf:vote><inf:voteRecord><inf:howVoted>FOR</inf:howVoted><inf:sharesVoted>14105</inf:sharesVoted><inf:managementRecommendation>FOR</inf:managementRecommendation></inf:voteRecord></inf:vote></inf:proxyTable>
<inf:proxyTable><inf:issuerName>QUIDELORTHO CORPORATION</inf:issuerName><inf:cusip>219798105</inf:cusip><inf:isin>US2197981051</inf:isin><inf:meetingDate>05/14/2024</inf:meetingDate><inf:voteDescription>Approval of, on an advisory basis, the compensation of QuidelOrtho's named executive officers.</inf:voteDescription><inf:voteCategories><inf:voteCategory><inf:categoryType>SECTION 14A SAY-ON-PAY VOTES</inf:categoryType></inf:voteCategory></inf:voteCategories><inf:voteSource>ISSUER</inf:voteSource><inf:sharesVoted>0</inf:sharesVoted><inf:sharesOnLoan>0</inf:sharesOnLoan><inf:vote><inf:voteRecord><inf:howVoted></inf:howVoted><inf:sharesVoted></inf:sharesVoted><inf:managementRecommendation></inf:managementRecommendation></inf:voteRecord></inf:vote></inf:proxyTable>
<inf:proxyTable><inf:issuerName>CYTOKINETICS, INCORPORATED</inf:issuerName><inf:cusip>23282W605</inf:cusip><inf:isin>US23282W6057</inf:isin><inf:meetingDate>05/15/2024</inf:meetingDate><inf:voteDescription>To approve, on an advisory basis, the compensation of the Company's named executive officers, as disclosed in the Proxy Statement.</inf:voteDescription><inf:voteCategories><inf:voteCategory><inf:categoryType>SECTION 14A SAY-ON-PAY VOTES</inf:categoryType></inf:voteCategory></inf:voteCategories><inf:voteSource>ISSUER</inf:voteSource><inf:sharesVoted>39020</inf:sharesVoted><inf:sharesOnLoan>0</inf:sharesOnLoan><inf:vote><inf:voteRecord><inf:howVoted>FOR</inf:howVoted><inf:sharesVoted>39020</inf:sharesVoted><inf:managementRecommendation>FOR</inf:managementRecommendation></inf:voteRecord></inf:vote></inf:proxyTable>
<inf:proxyTable><inf:issuerName>OPTION CARE HEALTH, INC.</inf:issuerName><inf:cusip>68404L201</inf:cusip><inf:isin>US68404L2016</inf:isin><inf:meetingDate>05/15/2024</inf:meetingDate><inf:voteDescription>To approve, on a non-binding advisory basis, our executive compensation.</inf:voteDescription><inf:voteCategories><inf:voteCategory><inf:categoryType>SECTION 14A SAY-ON-PAY VOTES</inf:categoryType></inf:voteCategory></inf:voteCategories><inf:voteSource>ISSUER</inf:voteSource><inf:sharesVoted>2402</inf:sharesVoted><inf:sharesOnLoan>0</inf:sharesOnLoan><inf:vote><inf:voteRecord><inf:howVoted>FOR</inf:howVoted><inf:sharesVoted>2402</inf:sharesVoted><inf:managementRecommendation>FOR</inf:managementRecommendation></inf:voteRecord></inf:vote></inf:proxyTable>
<inf:proxyTable><inf:issuerName>CORBUS PHARMACEUTICALS HOLDINGS, INC.</inf:issuerName><inf:cusip>21833P301</inf:cusip><inf:isin>US21833P3010</inf:isin><inf:meetingDate>05/16/2024</inf:meetingDate><inf:voteDescription>Approve, on an advisory basis, of the executive compensation of the Company's named executive officers</inf:voteDescription><inf:voteCategories><inf:voteCategory><inf:categoryType>SECTION 14A SAY-ON-PAY VOTES</inf:categoryType></inf:voteCategory></inf:voteCategories><inf:voteSource>ISSUER</inf:voteSource><inf:sharesVoted>45297</inf:sharesVoted><inf:sharesOnLoan>0</inf:sharesOnLoan><inf:vote><inf:voteRecord><inf:howVoted>FOR</inf:howVoted><inf:sharesVoted>45297</inf:sharesVoted><inf:managementRecommendation>FOR</inf:managementRecommendation></inf:voteRecord></inf:vote></inf:proxyTable>
<inf:proxyTable><inf:issuerName>CVS HEALTH CORPORATION</inf:issuerName><inf:cusip>126650100</inf:cusip><inf:isin>US1266501006</inf:isin><inf:meetingDate>05/16/2024</inf:meetingDate><inf:voteDescription>Say on Pay, a Proposal to Approve, on an Advisory Basis, the Company's Executive Compensation</inf:voteDescription><inf:voteCategories><inf:voteCategory><inf:categoryType>SECTION 14A SAY-ON-PAY VOTES</inf:categoryType></inf:voteCategory></inf:voteCategories><inf:voteSource>ISSUER</inf:voteSource><inf:sharesVoted>207</inf:sharesVoted><inf:sharesOnLoan>0</inf:sharesOnLoan><inf:vote><inf:voteRecord><inf:howVoted>FOR</inf:howVoted><inf:sharesVoted>207</inf:sharesVoted><inf:managementRecommendation>FOR</inf:managementRecommendation></inf:voteRecord></inf:vote></inf:proxyTable>
<inf:proxyTable><inf:issuerName>VIKING THERAPEUTICS INC</inf:issuerName><inf:cusip>92686J106</inf:cusip><inf:isin>US92686J1060</inf:isin><inf:meetingDate>05/21/2024</inf:meetingDate><inf:voteDescription>To approve, on an advisory basis, the compensation of our named executive officers</inf:voteDescription><inf:voteCategories><inf:voteCategory><inf:categoryType>SECTION 14A SAY-ON-PAY VOTES</inf:categoryType></inf:voteCategory></inf:voteCategories><inf:voteSource>ISSUER</inf:voteSource><inf:sharesVoted>281</inf:sharesVoted><inf:sharesOnLoan>0</inf:sharesOnLoan><inf:vote><inf:voteRecord><inf:howVoted>FOR</inf:howVoted><inf:sharesVoted>281</inf:sharesVoted><inf:managementRecommendation>FOR</inf:managementRecommendation></inf:voteRecord></inf:vote></inf:proxyTable>
<inf:proxyTable><inf:issuerName>DEXCOM, INC.</inf:issuerName><inf:cusip>252131107</inf:cusip><inf:isin>US2521311074</inf:isin><inf:meetingDate>05/22/2024</inf:meetingDate><inf:voteDescription>To provide a non-binding advisory vote on the compensation of our named executive officers for the fiscal year ended December 31, 2023</inf:voteDescription><inf:voteCategories><inf:voteCategory><inf:categoryType>SECTION 14A SAY-ON-PAY VOTES</inf:categoryType></inf:voteCategory></inf:voteCategories><inf:voteSource>ISSUER</inf:voteSource><inf:sharesVoted>2121</inf:sharesVoted><inf:sharesOnLoan>0</inf:sharesOnLoan><inf:vote><inf:voteRecord><inf:howVoted>FOR</inf:howVoted><inf:sharesVoted>2121</inf:sharesVoted><inf:managementRecommendation>FOR</inf:managementRecommendation></inf:voteRecord></inf:vote></inf:proxyTable>
<inf:proxyTable><inf:issuerName>NEUROCRINE BIOSCIENCES, INC.</inf:issuerName><inf:cusip>64125C109</inf:cusip><inf:isin>US64125C1099</inf:isin><inf:meetingDate>05/22/2024</inf:meetingDate><inf:voteDescription>Advisory vote on the compensation paid to the Company's named executive officers</inf:voteDescription><inf:voteCategories><inf:voteCategory><inf:categoryType>SECTION 14A SAY-ON-PAY VOTES</inf:categoryType></inf:voteCategory></inf:voteCategories><inf:voteSource>ISSUER</inf:voteSource><inf:sharesVoted>8212</inf:sharesVoted><inf:sharesOnLoan>0</inf:sharesOnLoan><inf:vote><inf:voteRecord><inf:howVoted>FOR</inf:howVoted><inf:sharesVoted>8212</inf:sharesVoted><inf:managementRecommendation>FOR</inf:managementRecommendation></inf:voteRecord></inf:vote></inf:proxyTable>
<inf:proxyTable><inf:issuerName>PRIVIA HEALTH, LLC.</inf:issuerName><inf:cusip>74276R102</inf:cusip><inf:isin>US74276R1023</inf:isin><inf:meetingDate>05/22/2024</inf:meetingDate><inf:voteDescription>To approve, on an advisory (non-binding) basis, the compensation of our named executive officers</inf:voteDescription><inf:voteCategories><inf:voteCategory><inf:categoryType>SECTION 14A SAY-ON-PAY VOTES</inf:categoryType></inf:voteCategory></inf:voteCategories><inf:voteSource>ISSUER</inf:voteSource><inf:sharesVoted>90</inf:sharesVoted><inf:sharesOnLoan>0</inf:sharesOnLoan><inf:vote><inf:voteRecord><inf:howVoted>FOR</inf:howVoted><inf:sharesVoted>90</inf:sharesVoted><inf:managementRecommendation>FOR</inf:managementRecommendation></inf:voteRecord></inf:vote></inf:proxyTable>
<inf:proxyTable><inf:issuerName>MARAVAI LIFESCIENCES HOLDINGS, INC.</inf:issuerName><inf:cusip>56600D107</inf:cusip><inf:isin>US56600D1072</inf:isin><inf:meetingDate>05/23/2024</inf:meetingDate><inf:voteDescription>To approve, on a non-binding advisory basis, the compensation of Maravai's named executive officers</inf:voteDescription><inf:voteCategories><inf:voteCategory><inf:categoryType>SECTION 14A SAY-ON-PAY VOTES</inf:categoryType></inf:voteCategory></inf:voteCategories><inf:voteSource>ISSUER</inf:voteSource><inf:sharesVoted>164920</inf:sharesVoted><inf:sharesOnLoan>0</inf:sharesOnLoan><inf:vote><inf:voteRecord><inf:howVoted>FOR</inf:howVoted><inf:sharesVoted>164920</inf:sharesVoted><inf:managementRecommendation>FOR</inf:managementRecommendation></inf:voteRecord></inf:vote></inf:proxyTable>
<inf:proxyTable><inf:issuerName>ORTHOPEDIATRICS CORP.</inf:issuerName><inf:cusip>68752L100</inf:cusip><inf:isin>US68752L1008</inf:isin><inf:meetingDate>05/24/2024</inf:meetingDate><inf:voteDescription>To approve, on an advisory basis, the compensation of our executive officers who are named in the compensation disclosures in the accompanying Proxy Statement</inf:voteDescription><inf:voteCategories><inf:voteCategory><inf:categoryType>SECTION 14A SAY-ON-PAY VOTES</inf:categoryType></inf:voteCategory></inf:voteCategories><inf:voteSource>ISSUER</inf:voteSource><inf:sharesVoted>167583</inf:sharesVoted><inf:sharesOnLoan>0</inf:sharesOnLoan><inf:vote><inf:voteRecord><inf:howVoted>FOR</inf:howVoted><inf:sharesVoted>167583</inf:sharesVoted><inf:managementRecommendation>FOR</inf:managementRecommendation></inf:voteRecord></inf:vote></inf:proxyTable>
<inf:proxyTable><inf:issuerName>ALKERMES PLC</inf:issuerName><inf:cusip>G01767105</inf:cusip><inf:isin>IE00B56GVS15</inf:isin><inf:meetingDate>05/31/2024</inf:meetingDate><inf:voteDescription>To approve, in a non-binding, advisory vote, the compensation of the Company's named executive officers</inf:voteDescription><inf:voteCategories><inf:voteCategory><inf:categoryType>SECTION 14A SAY-ON-PAY VOTES</inf:categoryType></inf:voteCategory></inf:voteCategories><inf:voteSource>ISSUER</inf:voteSource><inf:sharesVoted>171</inf:sharesVoted><inf:sharesOnLoan>0</inf:sharesOnLoan><inf:vote><inf:voteRecord><inf:howVoted>FOR</inf:howVoted><inf:sharesVoted>171</inf:sharesVoted><inf:managementRecommendation>FOR</inf:managementRecommendation></inf:voteRecord></inf:vote></inf:proxyTable>
<inf:proxyTable><inf:issuerName>ALKERMES PLC</inf:issuerName><inf:cusip>G01767105</inf:cusip><inf:isin>IE00B56GVS15</inf:isin><inf:meetingDate>05/31/2024</inf:meetingDate><inf:voteDescription>To approve, in a non-binding, advisory vote, the frequency of future advisory votes on the compensation of the Company's named executive officers</inf:voteDescription><inf:voteCategories><inf:voteCategory><inf:categoryType>SECTION 14A SAY-ON-PAY VOTES</inf:categoryType></inf:voteCategory></inf:voteCategories><inf:voteSource>ISSUER</inf:voteSource><inf:sharesVoted>171</inf:sharesVoted><inf:sharesOnLoan>0</inf:sharesOnLoan><inf:vote><inf:voteRecord><inf:howVoted>1 YEAR</inf:howVoted><inf:sharesVoted>171</inf:sharesVoted><inf:managementRecommendation>FOR</inf:managementRecommendation></inf:voteRecord></inf:vote></inf:proxyTable>
<inf:proxyTable><inf:issuerName>BARRETT BUSINESS SERVICES, INC.</inf:issuerName><inf:cusip>068463108</inf:cusip><inf:isin>US0684631080</inf:isin><inf:meetingDate>06/03/2024</inf:meetingDate><inf:voteDescription>Advisory vote to approve the compensation of our named executive officers</inf:voteDescription><inf:voteCategories><inf:voteCategory><inf:categoryType>SECTION 14A SAY-ON-PAY VOTES</inf:categoryType></inf:voteCategory></inf:voteCategories><inf:voteSource>ISSUER</inf:voteSource><inf:sharesVoted>10898</inf:sharesVoted><inf:sharesOnLoan>0</inf:sharesOnLoan><inf:vote><inf:voteRecord><inf:howVoted>FOR</inf:howVoted><inf:sharesVoted>10898</inf:sharesVoted><inf:managementRecommendation>FOR</inf:managementRecommendation></inf:voteRecord></inf:vote></inf:proxyTable>
<inf:proxyTable><inf:issuerName>RELAY THERAPEUTICS, INC.</inf:issuerName><inf:cusip>75943R102</inf:cusip><inf:isin>US75943R1023</inf:isin><inf:meetingDate>06/03/2024</inf:meetingDate><inf:voteDescription>To consider and act upon an advisory vote on the compensation of our named executive officers</inf:voteDescription><inf:voteCategories><inf:voteCategory><inf:categoryType>SECTION 14A SAY-ON-PAY VOTES</inf:categoryType></inf:voteCategory></inf:voteCategories><inf:voteSource>ISSUER</inf:voteSource><inf:sharesVoted>72034</inf:sharesVoted><inf:sharesOnLoan>0</inf:sharesOnLoan><inf:vote><inf:voteRecord><inf:howVoted>FOR</inf:howVoted><inf:sharesVoted>72034</inf:sharesVoted><inf:managementRecommendation>FOR</inf:managementRecommendation></inf:voteRecord></inf:vote></inf:proxyTable>
<inf:proxyTable><inf:issuerName>KURA ONCOLOGY, INC.</inf:issuerName><inf:cusip>50127T109</inf:cusip><inf:isin>US50127T1097</inf:isin><inf:meetingDate>06/05/2024</inf:meetingDate><inf:voteDescription>Approval, on an advisory basis, of the compensation of our named executive officers during the year ended December 31, 2023</inf:voteDescription><inf:voteCategories><inf:voteCategory><inf:categoryType>SECTION 14A SAY-ON-PAY VOTES</inf:categoryType></inf:voteCategory></inf:voteCategories><inf:voteSource>ISSUER</inf:voteSource><inf:sharesVoted>35164</inf:sharesVoted><inf:sharesOnLoan>0</inf:sharesOnLoan><inf:vote><inf:voteRecord><inf:howVoted>FOR</inf:howVoted><inf:sharesVoted>35164</inf:sharesVoted><inf:managementRecommendation>FOR</inf:managementRecommendation></inf:voteRecord></inf:vote></inf:proxyTable>
<inf:proxyTable><inf:issuerName>MIRUM PHARMACEUTICALS, INC.</inf:issuerName><inf:cusip>604749101</inf:cusip><inf:isin>US6047491013</inf:isin><inf:meetingDate>06/05/2024</inf:meetingDate><inf:voteDescription>To approve, on an advisory basis, the compensation of the Company's named executive officers, as disclosed in the Proxy Statement</inf:voteDescription><inf:voteCategories><inf:voteCategory><inf:categoryType>SECTION 14A SAY-ON-PAY VOTES</inf:categoryType></inf:voteCategory></inf:voteCategories><inf:voteSource>ISSUER</inf:voteSource><inf:sharesVoted>64677</inf:sharesVoted><inf:sharesOnLoan>0</inf:sharesOnLoan><inf:vote><inf:voteRecord><inf:howVoted>FOR</inf:howVoted><inf:sharesVoted>64677</inf:sharesVoted><inf:managementRecommendation>FOR</inf:managementRecommendation></inf:voteRecord></inf:vote></inf:proxyTable>
<inf:proxyTable><inf:issuerName>MIRUM PHARMACEUTICALS, INC.</inf:issuerName><inf:cusip>604749101</inf:cusip><inf:isin>US6047491013</inf:isin><inf:meetingDate>06/05/2024</inf:meetingDate><inf:voteDescription>To indicate, on an advisory basis, the preferred frequency of stockholder advisory votes on the compensation of the Company's named executive officers</inf:voteDescription><inf:voteCategories><inf:voteCategory><inf:categoryType>SECTION 14A SAY-ON-PAY VOTES</inf:categoryType></inf:voteCategory></inf:voteCategories><inf:voteSource>ISSUER</inf:voteSource><inf:sharesVoted>64677</inf:sharesVoted><inf:sharesOnLoan>0</inf:sharesOnLoan><inf:vote><inf:voteRecord><inf:howVoted>1 YEAR</inf:howVoted><inf:sharesVoted>64677</inf:sharesVoted><inf:managementRecommendation>FOR</inf:managementRecommendation></inf:voteRecord></inf:vote></inf:proxyTable>
<inf:proxyTable><inf:issuerName>MEIRAGTX HOLDINGS PLC</inf:issuerName><inf:cusip>G59665102</inf:cusip><inf:isin>KYG596651029</inf:isin><inf:meetingDate>06/06/2024</inf:meetingDate><inf:voteDescription>To approve, on an advisory (non-binding) basis, the compensation of the Company's named executive officers</inf:voteDescription><inf:voteCategories><inf:voteCategory><inf:categoryType>SECTION 14A SAY-ON-PAY VOTES</inf:categoryType></inf:voteCategory></inf:voteCategories><inf:voteSource>ISSUER</inf:voteSource><inf:sharesVoted>909815</inf:sharesVoted><inf:sharesOnLoan>0</inf:sharesOnLoan><inf:vote><inf:voteRecord><inf:howVoted>FOR</inf:howVoted><inf:sharesVoted>909815</inf:sharesVoted><inf:managementRecommendation>FOR</inf:managementRecommendation></inf:voteRecord></inf:vote></inf:proxyTable>
<inf:proxyTable><inf:issuerName>MEIRAGTX HOLDINGS PLC</inf:issuerName><inf:cusip>G59665102</inf:cusip><inf:isin>KYG596651029</inf:isin><inf:meetingDate>06/06/2024</inf:meetingDate><inf:voteDescription>To approve, on an advisory (non-binding) basis, the frequency of future advisory votes on the compensation of the Company's named executive officers</inf:voteDescription><inf:voteCategories><inf:voteCategory><inf:categoryType>SECTION 14A SAY-ON-PAY VOTES</inf:categoryType></inf:voteCategory></inf:voteCategories><inf:voteSource>ISSUER</inf:voteSource><inf:sharesVoted>909815</inf:sharesVoted><inf:sharesOnLoan>0</inf:sharesOnLoan><inf:vote><inf:voteRecord><inf:howVoted>3 YEARS</inf:howVoted><inf:sharesVoted>909815</inf:sharesVoted><inf:managementRecommendation>FOR</inf:managementRecommendation></inf:voteRecord></inf:vote></inf:proxyTable>
<inf:proxyTable><inf:issuerName>OVID THERAPEUTICS INC.</inf:issuerName><inf:cusip>690469101</inf:cusip><inf:isin>US6904691010</inf:isin><inf:meetingDate>06/06/2024</inf:meetingDate><inf:voteDescription>Advisory approval of the compensation paid to our named executive officers</inf:voteDescription><inf:voteCategories><inf:voteCategory><inf:categoryType>SECTION 14A SAY-ON-PAY VOTES</inf:categoryType></inf:voteCategory></inf:voteCategories><inf:voteSource>ISSUER</inf:voteSource><inf:sharesVoted>206007</inf:sharesVoted><inf:sharesOnLoan>0</inf:sharesOnLoan><inf:vote><inf:voteRecord><inf:howVoted>FOR</inf:howVoted><inf:sharesVoted>206007</inf:sharesVoted><inf:managementRecommendation>FOR</inf:managementRecommendation></inf:voteRecord></inf:vote></inf:proxyTable>
<inf:proxyTable><inf:issuerName>10X GENOMICS, INC.</inf:issuerName><inf:cusip>88025U109</inf:cusip><inf:isin>US88025U1097</inf:isin><inf:meetingDate>06/11/2024</inf:meetingDate><inf:voteDescription>A vote to approve, on a non-binding, advisory basis, the compensation of our named executive officers</inf:voteDescription><inf:voteCategories><inf:voteCategory><inf:categoryType>SECTION 14A SAY-ON-PAY VOTES</inf:categoryType></inf:voteCategory></inf:voteCategories><inf:voteSource>ISSUER</inf:voteSource><inf:sharesVoted>0</inf:sharesVoted><inf:sharesOnLoan>0</inf:sharesOnLoan><inf:vote><inf:voteRecord><inf:howVoted></inf:howVoted><inf:sharesVoted></inf:sharesVoted><inf:managementRecommendation></inf:managementRecommendation></inf:voteRecord></inf:vote></inf:proxyTable>
<inf:proxyTable><inf:issuerName>AVROBIO, INC.</inf:issuerName><inf:cusip>05455M100</inf:cusip><inf:isin>US05455M1009</inf:isin><inf:meetingDate>06/11/2024</inf:meetingDate><inf:voteDescription>The Executive Compensation Arrangements Proposal - To approve, on a non-binding advisory vote basis, compensation that will or may become payable by AVROBIO to its named executive officers in connection with the merger, each as described in the accompanying proxy statement/prospectus.</inf:voteDescription><inf:voteCategories><inf:voteCategory><inf:categoryType>SECTION 14A SAY-ON-PAY VOTES</inf:categoryType></inf:voteCategory></inf:voteCategories><inf:voteSource>ISSUER</inf:voteSource><inf:sharesVoted>177060</inf:sharesVoted><inf:sharesOnLoan>0</inf:sharesOnLoan><inf:vote><inf:voteRecord><inf:howVoted>FOR</inf:howVoted><inf:sharesVoted>177060</inf:sharesVoted><inf:managementRecommendation>FOR</inf:managementRecommendation></inf:voteRecord></inf:vote></inf:proxyTable>
<inf:proxyTable><inf:issuerName>PACIRA BIOSCIENCES, INC.</inf:issuerName><inf:cusip>695127100</inf:cusip><inf:isin>US6951271005</inf:isin><inf:meetingDate>06/11/2024</inf:meetingDate><inf:voteDescription>Approval, on an advisory basis, of the compensation of our named executive officers</inf:voteDescription><inf:voteCategories><inf:voteCategory><inf:categoryType>SECTION 14A SAY-ON-PAY VOTES</inf:categoryType></inf:voteCategory></inf:voteCategories><inf:voteSource>ISSUER</inf:voteSource><inf:sharesVoted>0</inf:sharesVoted><inf:sharesOnLoan>0</inf:sharesOnLoan><inf:vote><inf:voteRecord><inf:howVoted></inf:howVoted><inf:sharesVoted></inf:sharesVoted><inf:managementRecommendation></inf:managementRecommendation></inf:voteRecord></inf:vote></inf:proxyTable>
<inf:proxyTable><inf:issuerName>ALX ONCOLOGY HOLDINGS INC</inf:issuerName><inf:cusip>00166B105</inf:cusip><inf:isin>US00166B1052</inf:isin><inf:meetingDate>06/12/2024</inf:meetingDate><inf:voteDescription>Advisory vote to approve named executive officer compensation</inf:voteDescription><inf:voteCategories><inf:voteCategory><inf:categoryType>SECTION 14A SAY-ON-PAY VOTES</inf:categoryType></inf:voteCategory></inf:voteCategories><inf:voteSource>ISSUER</inf:voteSource><inf:sharesVoted>7201</inf:sharesVoted><inf:sharesOnLoan>0</inf:sharesOnLoan><inf:vote><inf:voteRecord><inf:howVoted>FOR</inf:howVoted><inf:sharesVoted>7201</inf:sharesVoted><inf:managementRecommendation>FOR</inf:managementRecommendation></inf:voteRecord></inf:vote></inf:proxyTable>
<inf:proxyTable><inf:issuerName>ANAPTYSBIO, INC.</inf:issuerName><inf:cusip>032724106</inf:cusip><inf:isin>US0327241065</inf:isin><inf:meetingDate>06/12/2024</inf:meetingDate><inf:voteDescription>To conduct a non-binding advisory vote on the compensation of our named executive officers as disclosed in the accompanying materials.</inf:voteDescription><inf:voteCategories><inf:voteCategory><inf:categoryType>SECTION 14A SAY-ON-PAY VOTES</inf:categoryType></inf:voteCategory></inf:voteCategories><inf:voteSource>ISSUER</inf:voteSource><inf:sharesVoted>0</inf:sharesVoted><inf:sharesOnLoan>0</inf:sharesOnLoan><inf:vote><inf:voteRecord><inf:howVoted></inf:howVoted><inf:sharesVoted></inf:sharesVoted><inf:managementRecommendation></inf:managementRecommendation></inf:voteRecord></inf:vote></inf:proxyTable>
<inf:proxyTable><inf:issuerName>BIOCRYST PHARMACEUTICALS, INC.</inf:issuerName><inf:cusip>09058V103</inf:cusip><inf:isin>US09058V1035</inf:isin><inf:meetingDate>06/12/2024</inf:meetingDate><inf:voteDescription>To approve, on an advisory basis, the Company's executive compensation.</inf:voteDescription><inf:voteCategories><inf:voteCategory><inf:categoryType>SECTION 14A SAY-ON-PAY VOTES</inf:categoryType></inf:voteCategory></inf:voteCategories><inf:voteSource>ISSUER</inf:voteSource><inf:sharesVoted>675464</inf:sharesVoted><inf:sharesOnLoan>0</inf:sharesOnLoan><inf:vote><inf:voteRecord><inf:howVoted>FOR</inf:howVoted><inf:sharesVoted>675464</inf:sharesVoted><inf:managementRecommendation>FOR</inf:managementRecommendation></inf:voteRecord></inf:vote></inf:proxyTable>
<inf:proxyTable><inf:issuerName>GUARDANT HEALTH, INC.</inf:issuerName><inf:cusip>40131M109</inf:cusip><inf:isin>US40131M1099</inf:isin><inf:meetingDate>06/12/2024</inf:meetingDate><inf:voteDescription>Non-binding advisory vote to approve Guardant Health, Inc.'s named executive officer compensation</inf:voteDescription><inf:voteCategories><inf:voteCategory><inf:categoryType>SECTION 14A SAY-ON-PAY VOTES</inf:categoryType></inf:voteCategory></inf:voteCategories><inf:voteSource>ISSUER</inf:voteSource><inf:sharesVoted>114087</inf:sharesVoted><inf:sharesOnLoan>0</inf:sharesOnLoan><inf:vote><inf:voteRecord><inf:howVoted>FOR</inf:howVoted><inf:sharesVoted>114087</inf:sharesVoted><inf:managementRecommendation>FOR</inf:managementRecommendation></inf:voteRecord></inf:vote></inf:proxyTable>
<inf:proxyTable><inf:issuerName>ABCELLERA BIOLOGICS INC.</inf:issuerName><inf:cusip>00288U106</inf:cusip><inf:isin>CA00288U1066</inf:isin><inf:meetingDate>06/13/2024</inf:meetingDate><inf:voteDescription>To approve, on a non-binding advisory basis, the compensation of the Company's named executive officers, or Say-on-Pay</inf:voteDescription><inf:voteCategories><inf:voteCategory><inf:categoryType>SECTION 14A SAY-ON-PAY VOTES</inf:categoryType></inf:voteCategory></inf:voteCategories><inf:voteSource>ISSUER</inf:voteSource><inf:sharesVoted>449</inf:sharesVoted><inf:sharesOnLoan>0</inf:sharesOnLoan><inf:vote><inf:voteRecord><inf:howVoted>FOR</inf:howVoted><inf:sharesVoted>449</inf:sharesVoted><inf:managementRecommendation>FOR</inf:managementRecommendation></inf:voteRecord></inf:vote></inf:proxyTable>
<inf:proxyTable><inf:issuerName>ADC THERAPEUTICS SA</inf:issuerName><inf:cusip>H0036K147</inf:cusip><inf:isin>CH0499880968</inf:isin><inf:meetingDate>06/13/2024</inf:meetingDate><inf:voteDescription>Approving, on an advisory basis under Swiss law, the Compensation Report: The Board of Directors proposes that the Company's Compensation Report for the year ended December 31, 2023, be approved in a non-binding advisory vote</inf:voteDescription><inf:voteCategories><inf:voteCategory><inf:categoryType>COMPENSATION</inf:categoryType></inf:voteCategory></inf:voteCategories><inf:voteSource>ISSUER</inf:voteSource><inf:sharesVoted>3485869</inf:sharesVoted><inf:sharesOnLoan>0</inf:sharesOnLoan><inf:vote><inf:voteRecord><inf:howVoted>FOR</inf:howVoted><inf:sharesVoted>3485869</inf:sharesVoted><inf:managementRecommendation>FOR</inf:managementRecommendation></inf:voteRecord></inf:vote></inf:proxyTable>
<inf:proxyTable><inf:issuerName>ADC THERAPEUTICS SA</inf:issuerName><inf:cusip>H0036K147</inf:cusip><inf:isin>CH0499880968</inf:isin><inf:meetingDate>06/13/2024</inf:meetingDate><inf:voteDescription>Approving, on an advisory basis under U.S. law, the compensation paid to the Named Executive Officers: The Board of Directors is proposing that the following proposal: "RESOLVED, that the shareholders approve, on an advisory basis under U.S. law, the compensation of the Company's Named Executive Officers, as disclosed in "Executive Compensation" and the related compensation tables and narrative disclosure in this proxy statement", be approved</inf:voteDescription><inf:voteCategories><inf:voteCategory><inf:categoryType>SECTION 14A SAY-ON-PAY VOTES</inf:categoryType></inf:voteCategory></inf:voteCategories><inf:voteSource>ISSUER</inf:voteSource><inf:sharesVoted>3485869</inf:sharesVoted><inf:sharesOnLoan>0</inf:sharesOnLoan><inf:vote><inf:voteRecord><inf:howVoted>FOR</inf:howVoted><inf:sharesVoted>3485869</inf:sharesVoted><inf:managementRecommendation>FOR</inf:managementRecommendation></inf:voteRecord></inf:vote></inf:proxyTable>
<inf:proxyTable><inf:issuerName>ADC THERAPEUTICS SA</inf:issuerName><inf:cusip>H0036K147</inf:cusip><inf:isin>CH0499880968</inf:isin><inf:meetingDate>06/13/2024</inf:meetingDate><inf:voteDescription>Approving, on an advisory basis under U.S. law, the frequency of future votes on the compensation paid to the Named Executive Officers: The Board of Directors is proposing that the shareholders advise on the frequency of future advisory votes on Named Executive Compensation by voting for either "ONE YEAR", "TWO YEARS" OR "THREE YEARS". The Board of Directors recommends shareholders vote ONE YEAR on this proposal</inf:voteDescription><inf:voteCategories><inf:voteCategory><inf:categoryType>SECTION 14A SAY-ON-PAY VOTES</inf:categoryType></inf:voteCategory></inf:voteCategories><inf:voteSource>ISSUER</inf:voteSource><inf:sharesVoted>3485869</inf:sharesVoted><inf:sharesOnLoan>0</inf:sharesOnLoan><inf:vote><inf:voteRecord><inf:howVoted>1 YEAR</inf:howVoted><inf:sharesVoted>3485869</inf:sharesVoted><inf:managementRecommendation>FOR</inf:managementRecommendation></inf:voteRecord></inf:vote></inf:proxyTable>
<inf:proxyTable><inf:issuerName>KEZAR LIFE SCIENCES, INC.</inf:issuerName><inf:cusip>49372L100</inf:cusip><inf:isin>US49372L1008</inf:isin><inf:meetingDate>06/18/2024</inf:meetingDate><inf:voteDescription>Advisory vote on the compensation paid to our named executive officers</inf:voteDescription><inf:voteCategories><inf:voteCategory><inf:categoryType>SECTION 14A SAY-ON-PAY VOTES</inf:categoryType></inf:voteCategory></inf:voteCategories><inf:voteSource>ISSUER</inf:voteSource><inf:sharesVoted>137154</inf:sharesVoted><inf:sharesOnLoan>0</inf:sharesOnLoan><inf:vote><inf:voteRecord><inf:howVoted>FOR</inf:howVoted><inf:sharesVoted>137154</inf:sharesVoted><inf:managementRecommendation>FOR</inf:managementRecommendation></inf:voteRecord></inf:vote></inf:proxyTable>
<inf:proxyTable><inf:issuerName>KEZAR LIFE SCIENCES, INC.</inf:issuerName><inf:cusip>49372L100</inf:cusip><inf:isin>US49372L1008</inf:isin><inf:meetingDate>06/18/2024</inf:meetingDate><inf:voteDescription>Preferred frequency of the advisory vote on the compensation paid to our named executive officers</inf:voteDescription><inf:voteCategories><inf:voteCategory><inf:categoryType>SECTION 14A SAY-ON-PAY VOTES</inf:categoryType></inf:voteCategory></inf:voteCategories><inf:voteSource>ISSUER</inf:voteSource><inf:sharesVoted>137154</inf:sharesVoted><inf:sharesOnLoan>0</inf:sharesOnLoan><inf:vote><inf:voteRecord><inf:howVoted>1 YEAR</inf:howVoted><inf:sharesVoted>137154</inf:sharesVoted><inf:managementRecommendation>FOR</inf:managementRecommendation></inf:voteRecord></inf:vote></inf:proxyTable>
<inf:proxyTable><inf:issuerName>BRIDGEBIO PHARMA INC.</inf:issuerName><inf:cusip>10806X102</inf:cusip><inf:isin>US10806X1028</inf:isin><inf:meetingDate>06/21/2024</inf:meetingDate><inf:voteDescription>To cast a non-binding, advisory vote to approve the compensation of the Company's named executive officers</inf:voteDescription><inf:voteCategories><inf:voteCategory><inf:categoryType>SECTION 14A SAY-ON-PAY VOTES</inf:categoryType></inf:voteCategory></inf:voteCategories><inf:voteSource>ISSUER</inf:voteSource><inf:sharesVoted>18704</inf:sharesVoted><inf:sharesOnLoan>0</inf:sharesOnLoan><inf:vote><inf:voteRecord><inf:howVoted>FOR</inf:howVoted><inf:sharesVoted>18704</inf:sharesVoted><inf:managementRecommendation>FOR</inf:managementRecommendation></inf:voteRecord></inf:vote></inf:proxyTable>
<inf:proxyTable><inf:issuerName>COGENT BIOSCIENCES, INC.</inf:issuerName><inf:cusip>19240Q201</inf:cusip><inf:isin>US19240Q2012</inf:isin><inf:meetingDate>06/05/2024</inf:meetingDate><inf:voteDescription>Approval, on a non-binding, advisory basis, of the compensati on of the Company'snamed executive officers.</inf:voteDescription><inf:voteCategories><inf:voteCategory><inf:categoryType>SECTION 14A SAY-ON-PAY VOTES</inf:categoryType></inf:voteCategory></inf:voteCategories><inf:voteSource>ISSUER</inf:voteSource><inf:sharesVoted>194723</inf:sharesVoted><inf:sharesOnLoan>0</inf:sharesOnLoan><inf:vote><inf:voteRecord><inf:howVoted>FOR</inf:howVoted><inf:sharesVoted>194723</inf:sharesVoted><inf:managementRecommendation>FOR</inf:managementRecommendation></inf:voteRecord></inf:vote></inf:proxyTable>
<inf:proxyTable><inf:issuerName>INARI MEDICAL, INC.</inf:issuerName><inf:cusip>45332Y109</inf:cusip><inf:isin>US45332Y1091</inf:isin><inf:meetingDate>04/24/2024</inf:meetingDate><inf:voteDescription>To approve, on an advisory basis, the compensation of our named executive officers</inf:voteDescription><inf:voteCategories><inf:voteCategory><inf:categoryType>SECTION 14A SAY-ON-PAY VOTES</inf:categoryType></inf:voteCategory></inf:voteCategories><inf:voteSource>ISSUER</inf:voteSource><inf:sharesVoted>9765</inf:sharesVoted><inf:sharesOnLoan>0</inf:sharesOnLoan><inf:vote><inf:voteRecord><inf:howVoted>FOR</inf:howVoted><inf:sharesVoted>9765</inf:sharesVoted><inf:managementRecommendation>FOR</inf:managementRecommendation></inf:voteRecord></inf:vote></inf:proxyTable>
</inf:proxyVoteTable>
